PROTAC CDK9 Degrader-1

Target: Targets CDK9 cyclin-dependent kinase for experimental targeted protein degradation studies.

Binding Site: Binds the CDK9 ATP-binding pocket and cereblon thalidomide-binding domain to support productive ternary complex formation.

Mechanism of Action: PROTAC CDK9 Degrader-1 is designed for use in PROTAC or targeted protein degradation experiments directed toward CDK9 cyclin-dependent kinase. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

• PROTAC-Mediated CDK9 Degradation: This product is designed for the selective degradation of Cyclin-Dependent Kinase 9 (CDK9), a crucial regulator of transcription elongation. By facilitating the ubiquitination and subsequent proteasomal degradation of CDK9, researchers can study the effects of its depletion on gene expression and cell cycle progression.

• Targeted Protein Degradation in Cancer Research: PROTAC CDK9 Degrader-1 is instrumental in investigating the role of CDK9 in cancer cell survival. By targeting CDK9 for degradation, researchers can explore therapeutic strategies to disrupt aberrant transcriptional programs in cancer cells, providing insights into novel anti-cancer approaches.

• Functional Genomics via PROTACs: Utilize this degrader to dissect the functional role of CDK9 in various cellular processes. By achieving targeted protein degradation, researchers can perform loss-of-function studies to understand CDK9's involvement in transcriptional regulation, potentially revealing new biological pathways and targets.

• Drug Discovery and Development: PROTAC CDK9 Degrader-1 serves as a valuable tool in the early stages of drug discovery. By degrading CDK9, researchers can evaluate its potential as a therapeutic target and screen for synergistic effects with other compounds, accelerating the development of innovative treatments.